Clo­vis shares tank af­ter in­vestors size up the dis­ap­point­ing da­ta on ru­ca­parib

Clo­vis On­col­o­gy’s shares got ham­mered this morn­ing af­ter the biotech re­vealed some mixed re­sults for its PARP in­hibitor ru­ca­parib.

The biotech re­port­ed a 54% ob­jec­tive re­sponse rate for the drug for BR­CA-mu­tat­ed ovar­i­an can­cer, with nine (9%) com­plete re­spon­ders and 48 (45%) par­tial re­spon­ders. Bor­ing down in­to the da­ta, in­ves­ti­ga­tors al­so re­port­ed ze­ro re­sponse among the 7% of the pa­tients who were plat­inum-re­frac­to­ry, a 25% re­sponse rate for plat­inum-re­sis­tant pa­tients and 66% for plat­inum-sen­si­tive re­spons­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA